Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 20 unusual trades.

Delving into the details, we found 65% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $181,766, and 17 were calls, valued at $1,446,206.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $33.0 for Pfizer, spanning the last three months.

Analyzing Volume & Open Interest

In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 15393.88 with a total volume of 4,885.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Pfizer's big money trades within a strike price range of $20.0 to $33.0 over the last 30 days.

Pfizer 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Pfizer's Current Market Status

• With a trading volume of 9,819,447, the price of PFE is up by 0.63%, reaching $27.98.
• Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
• Next earnings report is scheduled for 32 days from now.

Professional Analyst Ratings for Pfizer

A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $45.0.

• Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
• An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
• An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.